voltion-discover
logo-discover
Enabling drug developers and scientists access to a range of state-of-the-art assays for rapid epigenetic profiling.
Overview

Rapid epigenetic profiling for drug developers.

What is Nu.Q® Discover?

Our Nu.Q® Discover program enables drug developers and scientists access to a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to market ready.

Nu.Q® Discover is built on our proprietary nucleosome quantification technology. It is an invaluable research tool for R&D professionals working within the field of pharmacoepigenetics, studying the epigenetic basis for variation in response to drugs.

volition-discover-2
0

Labs around the world using Nu.Q® Discover

0

Assays available

You can use our assays to answer your clinical questions, such as measuring treatment efficacy, or on-target and off-target effects in drug development.

icon-microscope-white

The role of nucleosomes and H3.1

Nucleosomes are small fragments of chromosomes released into the blood during cell death and consist of a histone octamer core with DNA wrapped around it. Histone proteins could be modified by a variety of post-translational modifications (PTMs) also called epigenetic modifications, such as methylation, acetylation, phosphorylation or citrullination. In epigenetics, modifications to histones, including H3, play a key role in regulating gene expression.

icon-clock-white

Measuring and monitoring

Measuring and monitoring nucleosome levels and modifications in circulating blood has the potential to aid diagnosis, prognosis and monitoring of many human diseases.

Nu.Q® Discover is built on Volition’s cutting-edge nucleosome quantification technology and adds value across the drug development pipeline, with applications in:

  • Oncology
  • Neurodegenerative diseases
  • Autoimmune diseases
  • NETosis
icon-computer-white

Our biomarkers

Our biomarkers support the entire drug discovery and development process from pre-clinical testing to market-ready. We aim to assess disease severity, monitor treatment response, and enhance the understanding of disease pathology and treatments.

Screenshot 2024-04-04 at 14.46.32
Nu.Q® Discover supporting drug development

Who can work with us?

If you are a pharmaceutical company or an academic research institution, you can access our range of state-of-the-art assays to answer your clinical questions, such as measuring treatment efficacy or on-target and off-target effects in drug development.

If you are a drug developer or scientist you can either:

  • Buy our Nu.Q® Discover H3.1 Research Use Only Assay directly.
  • Or work with us, access our assays and realize your longer term, drug development needs.
“Epigenetic biomarkers are a valuable tool from target identification to validation in clinical studies and being able to access rapid and sensitive testing generates transformative results.”
Terry Kelly
Chief Innovation Officer, Volition